License of Ocera’s MATCH(TM) Discovery Platform Supports Licensee’s Drug Discovery Programs
PALO ALTO, CA, USA I December 17, 2013 I Ocera Therapeutics (OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH(TM)) discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH(TM) technology, and grant a license to Genentech and Roche under Ocera’s related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4 million.
“Both the Genentech and Roche research organizations have an interest in the application of our MATCH(TM) technology,” said Linda Grais, M.D., J.D., chief executive officer of Ocera. “We are excited that we have found a good home for this technology where it may benefit the Roche Group and ultimately patients, while we focus our efforts on clinical development of OCR-002, our product candidate for the treatment of hepatic encephalopathy, a serious liver disorder.”
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger which has been granted Orphan Disease and Fast Track status from the FDA to treat hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. For additional information, please see www.ocerainc.com.
SOURCE: Ocera Therapeutics
Post Views: 180
License of Ocera’s MATCH(TM) Discovery Platform Supports Licensee’s Drug Discovery Programs
PALO ALTO, CA, USA I December 17, 2013 I Ocera Therapeutics (OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH(TM)) discovery platform. Under the terms of the agreement, Ocera will transfer ownership of equipment and materials related to the use of the MATCH(TM) technology, and grant a license to Genentech and Roche under Ocera’s related intellectual property rights. The Roche Group will make a one-time payment to Ocera of $4 million.
“Both the Genentech and Roche research organizations have an interest in the application of our MATCH(TM) technology,” said Linda Grais, M.D., J.D., chief executive officer of Ocera. “We are excited that we have found a good home for this technology where it may benefit the Roche Group and ultimately patients, while we focus our efforts on clinical development of OCR-002, our product candidate for the treatment of hepatic encephalopathy, a serious liver disorder.”
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger which has been granted Orphan Disease and Fast Track status from the FDA to treat hyperammonemia and associated hepatic encephalopathy in patients with liver cirrhosis, acute liver failure and acute liver injury. For additional information, please see www.ocerainc.com.
SOURCE: Ocera Therapeutics
Post Views: 180
